Baker McKenzie has advised a consortium of investors led by SPE Capital, through its Private Equity Fund III (PEF III), on its investment in a European holding company, the parent company of Orchidia Pharmaceutical Industries S.A.E., a leading ophthalmic pharmaceutical manufacturer with operations in Egypt and across the Middle East and Africa.
The investor consortium included the European Bank for Reconstruction and Development (EBRD), Société de Promotion et de Participation pour la Coopération Économique (Proparco), and the Belgian Investment Company for Developing Countries (BIO). The transaction was successfully completed in March 2026.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
